Copper-67 as a therapeutic nuclide for radioimmunotherapy

Bnl-61356 Development and Evaluation of Copper-67 and Samarium- 153 Labeled Conjugates for Tumor Radioimmunotherapy

The potential of utilizing receptor-specific agents such as monoclonal antibodies (MAb), and MAb-derived smaller molecules, as carriers of radionuclides for the selective destruction of tumors has stimulated much research activity (Srivastava, 1988; Larson, 1994). The success of such applications depends on many factors, especially the tumor binding properties of the antibody reagent, the effic...

Re-assessing gallium-67 as a therapeutic radionuclide☆

INTRODUCTION Despite its desirable half-life and low energy Auger electrons that travel further than for other radionuclides, 67Ga has been neglected as a therapeutic radionuclide. Here, 67Ga is compared with Auger electron emitter 111In as a potential therapeutic radionuclide. METHODS Plasmid pBR322 studies allowed direct comparison between 67Ga and 111In (1MBq) in causing DNA damage, includ...

Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy.

BACKGROUND We previously described a two-antibody model of (64)Cu radioimmunotherapy to evaluate low-dose, solid-tumor response. This model was designed to test the hypothesis that cellular internalization is critical in causing tumor cell death by mechanisms in addition to radiation damage. The purpose of the present study was to estimate radiation dosimetry for both antibodies (mAbs) using po...

Metabolism of copper 67 by the copper-deficient rat.

Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections

There is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment, has been successfully adapted for the treatment of experimental fungal, bacterial, and viral inf...